CN101107234A - 抑制hiv的2-(4-氰基苯氨基)嘧啶衍生物 - Google Patents
抑制hiv的2-(4-氰基苯氨基)嘧啶衍生物 Download PDFInfo
- Publication number
- CN101107234A CN101107234A CNA2006800031094A CN200680003109A CN101107234A CN 101107234 A CN101107234 A CN 101107234A CN A2006800031094 A CNA2006800031094 A CN A2006800031094A CN 200680003109 A CN200680003109 A CN 200680003109A CN 101107234 A CN101107234 A CN 101107234A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- reaction
- hiv
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
化合物编号 | IIIB | A | B | C | D | E | F |
1 | 9.2 | 8.4 | 9.4 | 9.1 | 9.1 | 8.4 | 8.4 |
2 | 8.5 | 7.8 | 8.5 | 7.7 | 8.4 | 8.1 | 7.7 |
3 | 8.3 | 7.1 | 8.1 | 5.8 | 7.4 | 5.2 | 6.6 |
Claims (7)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05100521.3 | 2005-01-27 | ||
EP05100521 | 2005-01-27 | ||
PCT/EP2006/050490 WO2006079656A1 (en) | 2005-01-27 | 2006-01-27 | Hiv inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101107234A true CN101107234A (zh) | 2008-01-16 |
CN101107234B CN101107234B (zh) | 2013-06-19 |
Family
ID=34938584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006800031094A Expired - Fee Related CN101107234B (zh) | 2005-01-27 | 2006-01-27 | 抑制hiv的2-(4-氰基苯氨基)嘧啶衍生物 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090124644A1 (zh) |
EP (2) | EP1853568B1 (zh) |
JP (2) | JP5190272B2 (zh) |
CN (1) | CN101107234B (zh) |
AT (1) | ATE523498T1 (zh) |
AU (1) | AU2006208778B2 (zh) |
BR (1) | BRPI0607214B8 (zh) |
CA (1) | CA2599228C (zh) |
ES (1) | ES2373820T3 (zh) |
MX (1) | MX2007009015A (zh) |
RU (1) | RU2403245C2 (zh) |
WO (1) | WO2006079656A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102718720A (zh) * | 2012-07-04 | 2012-10-10 | 宁波九胜创新医药科技有限公司 | 4-[(4,6-二氯-2-嘧啶基)氨基]苯腈的制备方法 |
CN102731414A (zh) * | 2012-07-04 | 2012-10-17 | 宁波九胜创新医药科技有限公司 | 4-[(4-氯-2-嘧啶基)氨基]苯腈的制备方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1853567B1 (en) * | 2005-02-18 | 2014-12-31 | Janssen R&D Ireland | Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives |
AU2006306984A1 (en) * | 2005-10-27 | 2007-05-03 | Teijin Pharma Limited | Benzo[b]thiophen derivative and process for production thereof |
US9006243B2 (en) * | 2006-12-29 | 2015-04-14 | Janssen R&D Ireland | HIV inhibiting 6-substituted pyrimidines |
AU2007341228B2 (en) * | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
WO2010150279A2 (en) * | 2009-06-22 | 2010-12-29 | Emcure Pharmaceuticals Limited | Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor |
WO2011017079A1 (en) | 2009-07-27 | 2011-02-10 | Teva Pharmaceutical Industries Ltd. | Process for the preparation and purification of etravirine and intermediates thereof |
WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
RU2729792C1 (ru) * | 2019-07-29 | 2020-08-12 | Акционерное общество "Научно-производственное объединение "ДОМ ФАРМАЦИИ" | Способы повышения растворимости лекарственного средства на основе пиримидинового производного бензофенона |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
IL123654A (en) | 1995-11-23 | 2001-08-08 | Janssen Pharmaceutica Nv | Process for the preparation of solid mixtures of cyclodextrins and pharmaceutical preparations containing such solid mixtures |
SK287270B6 (sk) * | 1998-11-10 | 2010-05-07 | Janssen Pharmaceutica N. V. | Derivát pyrimidínu |
US20050239054A1 (en) * | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
-
2006
- 2006-01-27 BR BRPI0607214A patent/BRPI0607214B8/pt not_active IP Right Cessation
- 2006-01-27 JP JP2007552651A patent/JP5190272B2/ja not_active Expired - Fee Related
- 2006-01-27 US US11/813,772 patent/US20090124644A1/en not_active Abandoned
- 2006-01-27 RU RU2007132179/04A patent/RU2403245C2/ru active
- 2006-01-27 CA CA2599228A patent/CA2599228C/en not_active Expired - Fee Related
- 2006-01-27 ES ES06707872T patent/ES2373820T3/es active Active
- 2006-01-27 AT AT06707872T patent/ATE523498T1/de not_active IP Right Cessation
- 2006-01-27 AU AU2006208778A patent/AU2006208778B2/en not_active Ceased
- 2006-01-27 EP EP06707872A patent/EP1853568B1/en active Active
- 2006-01-27 WO PCT/EP2006/050490 patent/WO2006079656A1/en active Application Filing
- 2006-01-27 CN CN2006800031094A patent/CN101107234B/zh not_active Expired - Fee Related
- 2006-01-27 EP EP11177764A patent/EP2388249A1/en not_active Ceased
- 2006-01-27 MX MX2007009015A patent/MX2007009015A/es active IP Right Grant
-
2012
- 2012-12-17 JP JP2012274674A patent/JP2013082722A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102718720A (zh) * | 2012-07-04 | 2012-10-10 | 宁波九胜创新医药科技有限公司 | 4-[(4,6-二氯-2-嘧啶基)氨基]苯腈的制备方法 |
CN102731414A (zh) * | 2012-07-04 | 2012-10-17 | 宁波九胜创新医药科技有限公司 | 4-[(4-氯-2-嘧啶基)氨基]苯腈的制备方法 |
CN102731414B (zh) * | 2012-07-04 | 2014-11-26 | 宁波九胜创新医药科技有限公司 | 4-[(4-氯-2-嘧啶基)氨基]苯腈的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1853568A1 (en) | 2007-11-14 |
JP2008528554A (ja) | 2008-07-31 |
ES2373820T3 (es) | 2012-02-09 |
CA2599228A1 (en) | 2006-08-03 |
EP1853568B1 (en) | 2011-09-07 |
RU2007132179A (ru) | 2009-03-10 |
CN101107234B (zh) | 2013-06-19 |
CA2599228C (en) | 2014-05-13 |
RU2403245C2 (ru) | 2010-11-10 |
JP2013082722A (ja) | 2013-05-09 |
BRPI0607214A2 (pt) | 2009-08-18 |
AU2006208778B2 (en) | 2012-08-09 |
US20090124644A1 (en) | 2009-05-14 |
BRPI0607214B8 (pt) | 2021-05-25 |
WO2006079656A1 (en) | 2006-08-03 |
BRPI0607214B1 (pt) | 2019-09-10 |
MX2007009015A (es) | 2007-09-18 |
ATE523498T1 (de) | 2011-09-15 |
JP5190272B2 (ja) | 2013-04-24 |
AU2006208778A1 (en) | 2006-08-03 |
EP2388249A1 (en) | 2011-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101107234B (zh) | 抑制hiv的2-(4-氰基苯氨基)嘧啶衍生物 | |
CN101119976B (zh) | 抑制hiv的2-(4-氰基苯氨基)嘧啶氧化物衍生物 | |
CN101031550B (zh) | 抑制hiv的5-碳环-或杂环取代的嘧啶类 | |
CN101048410B (zh) | 抑制hiv的双环嘧啶衍生物 | |
CN1751031B (zh) | 抑制hiv复制的嘧啶 | |
CN101031558B (zh) | 抑制人类免疫缺陷病毒的5-杂环基嘧啶 | |
CN100475815C (zh) | 抑制hiv复制的嘌呤衍生物 | |
CN101133038B (zh) | 抑制hiv的2-(4-氰基苯基)-6-羟氨基嘧啶 | |
CN101027288B (zh) | 抑制hiv的5-取代嘧啶 | |
CN101103029B (zh) | 作为抗感染剂的1,5,6-取代的-2-氧代-3-氰基-1,6a-二氮杂-四氢-荧蒽 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: IRELAND JANSSEN R + D COMPANY Free format text: FORMER OWNER: JANSSEN R + D IRELAND Effective date: 20150716 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: JANSSEN R + D IRELAND Free format text: FORMER NAME: TIBOTEC PHARM LTD. Owner name: TIBOTEC PHARM LTD. Free format text: FORMER NAME: TIBOTEC NV |
|
CP01 | Change in the name or title of a patent holder |
Address after: The Irish Village Patentee after: JANSSEN R&D IRELAND Address before: The Irish Village Patentee before: TIBOTEC PHARMACEUTICALS Address after: The Irish Village Patentee after: TIBOTEC PHARMACEUTICALS Address before: The Irish Village Patentee before: TIBOTEC PHARMACEUTICALS Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150716 Address after: The Irish Village Patentee after: JANSSEN R&D IRELAND Address before: The Irish Village Patentee before: JANSSEN R&D IRELAND |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130619 Termination date: 20220127 |
|
CF01 | Termination of patent right due to non-payment of annual fee |